A synthesis of oral morphine equivalents (OME) for opioid utilisation studies

被引:428
作者
Nielsen, Suzanne [1 ,2 ]
Degenhardt, Louisa [1 ]
Hoban, Bianca [1 ]
Gisev, Natasa [1 ]
机构
[1] Natl Drug & Alcohol Res Ctr, Randwick, NSW, Australia
[2] South Eastern Sydney Local Hlth Dist, Drug & Alcohol Serv, Sydney, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
opioids; drug utilisation; pain; pharmacoepidemiology;
D O I
10.1002/pds.3945
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeOral Morphine Equivalent (OME) doses are increasingly being used as a metric to represent opioid use. Driven by a growing need from pharmacoepidemiological studies, the objective of this study was to develop a comprehensive OME conversion table that can be used by researchers to calculate OMEs in a consistent and systematic way. MethodsClinical guidelines and literature sources were collated and synthesised to develop recommended OME conversion factors that can be used for research studies on opioids (including different formulations and routes of administration) currently available internationally including Australia, the United Kingdom, Europe, the United States and Canada. ResultsNo single resource includes all opioids that are currently available. Although there was some variation in conversion factors reported in different sources, overall, suggested conversion factors were mostly consistent across national and international sources. ConclusionsThe use of the OME metric appears optimal for opioid utilisation studies as it facilities both interpretation and comparison between opioids and geographical locations. We have presented a synthesis of published OME conversion factors that can be applied to pharmacoepidemiological studies of opioids, in addition to a discussion of the considerations and caveats in using OME as a metric for opioid use. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:733 / 737
页数:5
相关论文
共 17 条
[1]  
[Anonymous], OP CONV TABL
[2]  
[Anonymous], 2013, AUSTR MED HDB
[3]  
[Anonymous], 2015, MICR 2 0 TRUV HLTH A
[4]  
[Anonymous], J PALLIAT MED
[5]   Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC [J].
Caraceni, Augusto ;
Hanks, Geoff Rey ;
Kaasa, Stein ;
Bennett, Michael I. ;
Brunelli, Cinzia ;
Cherny, Nathan ;
Dale, Ola ;
De Conno, Franco ;
Fallon, Marie ;
Hanna, Magdi ;
Haugen, Dagny Faksvag ;
Juhl, Gitte ;
King, Samuel ;
Klepstad, Pal ;
Laugsand, Eivor A. ;
Maltoni, Marco ;
Mercadante, Sebastiano ;
Nabal, Maria ;
Pigni, Alessandra ;
Radbruch, Lukas ;
Reid, Colette ;
Sjogren, Per ;
Stone, Patrick C. ;
Tassinari, Davide ;
Zeppetella, Giovambattista .
LANCET ONCOLOGY, 2012, 13 (02) :E58-E68
[6]  
International Narcotics Control Board, 2011, GLOBAL OPIOID CONSUM
[7]  
Joint Formulary Committee, 2013, BRIT NAT FORM BNF 66, P224
[8]  
Lexi-comp, 2014, DRUG INFORM HDB, P1
[9]   The prescription drug epidemic in the United States: A perfect storm [J].
Maxwell, Jane Carlisle .
DRUG AND ALCOHOL REVIEW, 2011, 30 (03) :264-270
[10]   Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids [J].
Mercadante, Sebastiano ;
Porzio, Giampiero ;
Aielli, Federica ;
Adile, Claudio ;
Verna, Lucilla ;
Ficorella, Corrado ;
Giarratano, Antonello ;
Casuccio, Alessandra .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (06) :661-666